Boehringer Ingelheim News

Indianapolis/ IN/USA, and Ingelheim/Germany, 10th December 2008– Duloxetine hydrochloride (Cymbalta®/Xeristar®), administered at 60 to 120 mg once daily, delayed the onset of a new episode of depression in patients with recurrent depressive disorder, compared with placebo (p<.001), according to new data from an international study presented at a meeting of a major scientific society.

Ingelheim/Germany, 19 November 2008 (World COPD Day) – The independent judging panel* of the Eloquium Award have today named three journalists as winners of the 2008 competition for excellence in reporting on chronic obstructive pulmonary disease (COPD).

Ingelheim/Germany, 17 November 2008 - Boehringer Ingelheim has marked a new milestone within its rapidly expanding oncology portfolio with the announcement today that the company has progressed another of its oncology compounds into pivotal phase III clinical development.

New Orleans, 11 November 2008 - Long-term data for Pradaxa® (dabigatran etexilate) in the prevention of thromboembolic events in patients with recurrent, persistent and chronic AF was presented today at the 80th American Heart Association annual congress.1 PETRO-Ex is an open-label extension of the Prevention of Embolic and Thrombotic Events Study in Patients with AF Randomised to dabigatran (PET

Ingelheimm/Germany, 31 October 2008 - Results from the PRESIDE* survey, the largest study assessing the prevalence of female sexual problems, show that low sexual desire is the most commonly reported sexual problem in women aged 18 or older.1 In the new survey of more than 31,000 women, published today in Obstetrics & Gynecology (the Green Journal), nearly one in 10 women said they experience low desire with sexually-related personal distress, a condition that is medically referred to as Hypoactive Sexual Desire Disorder (HSDD).1

HSDD, is defined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) of the American Psychiatric Association, as diminished feelings of sexual interest or desire, absent sexual thoughts or fantasies and lack of responsive desire that causes marked distress or interpersonal difficulties and is not caused by a medical condition or drug.2 HSDD is a medical condition that remains largely under-diagnosed.3

Ingelheim, Munich / Germany, 30 October 2008 - For his milestone discoveries on the development of diabetes, Prof. Markus Stoffel from the Institute of Molecular Systems Biology at the ETH Zurich was today awarded the Heinrich Wieland Prize, one of the most treasured science awards in Germany. He received the distinction with EUR 50,000 prize money for his work in deciphering important mechanisms of blood sugar regulation and lipid metabolism in the body.

During the award ceremony at the Ludwig-Maximillians-Universität in Munich, the renowned internist with a research focus on nutrition Prof. Nepomuk Zöllner was honored, as well, with the Heinrich Wieland “Medal in Gold” for his lifetime achievement in gout research.

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a negative opinion for a Cymbalta® (duloxetine hydrochloride) application for the treatment of fibromyalgia.

“Eli Lilly and Company and Boehringer Ingelheim are naturally disappointed by the CHMP’s opinion,” said James Russell, M.D., medical director, Eli Lilly and Company. “We remain confident in the duloxetine data.”

No medication has been approved in Europe for the treatment of fibromyalgia, a disease characterized by chronic widespread pain.

The CHMP received data on the use of duloxetine in the treatment of fibromyalgia in 1,411 patients in four placebo-controlled studies and 350 patients in one open-label safety study, a total of 1,761 patients in five clinical trials.1-5

Beijing/China, 23 October 2008 – New results from the landmark ONTARGET® Trial show that, in Asian patients at high risk of cardiovascular disease (CVD) telmisartan (Micardis® ) 80mg is as effective as, and significantly better tolerated than, ramipril 10mg in reducing the risk of cardiovascular death, heart attack, stroke and hospitalisation for congestive heart failure.1 These preliminary results were presented today at the 19th Great Wall - International Cardiology Congress (GW-ICC) in Beijing, China.

Ingelheim/Germany, 22 October 2008 – Boehringer Ingelheim’s most promising new cell cycle kinase inhibitor and potentially first-in-class compound, BI 6727, has shown encouraging results in a phase I clinical trial in patients with advanced tumours who have failed to respond to other treatments.1 The data, presented today at a prestigious plenary session and included in the official press conference of the 20th EORTC-NCI-AACR Symposium in Geneva, Switzerland, is testament to the company’s ongoing commitment to research and development of innovative cancer treatments in areas of significant unmet medical need. Boehringer Ingelheim’s research efforts are focused on three main areas: angiokinase inhibition, signal transduction inhibition and cell cycle kinase inhibition, under which BI 6727 falls.

From Curiosity to Discovery: Boehringer Ingelheim’s pipeline update unveils novel investigational compounds heralding the Company’s entry into Type 2 Diabetes